Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 12/20 | 0.47 |
| ▸ | CTSD | P07339 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039944 | 0.95 | DPP4 (0.52) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29452652 | 0.93 | DPP4 (0.54) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29406740 | 0.91 | BACE1 (0.50) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29733242 | 0.88 | BACE1 (0.56) | BACE1CTSDBACE2 | |
| SCHEMBL537130 | 0.88 | DPP4 (0.59) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL5970284 | 0.88 | DPP4 (0.59) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30900797 | 0.87 | BACE1 (0.46) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL5970526 | 0.86 | DPP4 (0.58) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL4388337 | 0.86 | DPP4 (0.58) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29420865 | 0.85 | BACE1 (0.53) | DPP4DPP8DPP9BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | THE BOOTS COMPANY PLC (GB) | 2026-04-07 | — | — | US | claimed |
| WO-2026046854-A1 | PEPTIDE CONTAINING HYDROGEL COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 2026-03-05 | — | — | WO | claimed |
| EP-4702985-A1 | COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | The Boots Company PLC (GB) | 2026-03-04 | — | — | EP | claimed |
| WO-2025215348-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | claimed |
| WO-2025215349-A1 | HAIR GROWTH RESTORATION | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | claimed |
| EP-4631518-A1 | COMPOSITIONS FOR TREATING DISEASES OF THE AIRWAYS | The Boots Company plc (GB) | 2025-10-15 | — | — | EP | claimed |
| CN-119599379-A | Reservoir optimal scheduling method oriented to scheduling plan | 中国水利水电科学研究院 | 2025-03-11 | — | — | CN | claimed |
| US-20250054582-A1 | METHOD OF IDENTIFYING A SOLVENT FOR A MATRIKINE | THE BOOTS COMPANY PLC (GB) | 2025-02-13 | — | — | US | claimed |
| US-20240350391-A1 | COSMETIC COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 2024-10-24 | — | — | US | claimed |
| EP-4396827-A1 | METHOD FOR IDENTIFYING A SOLVENT FOR A MATRIKINE | The Boots Company PLC (GB) | 2024-07-10 | — | — | EP | claimed |
| US-20230414477-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2023-12-28 | — | — | US | claimed |
| CN-116872756-A | Charging information processing method, battery management device, medium and controller | 联合汽车电子有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-4247328-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2023-09-27 | — | — | EP | claimed |
| CN-116744894-A | Tetrapeptides and compositions comprising same | 布茨公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2023030680-A1 | METHOD FOR IDENTIFYING A SOLVENT FOR A MATRIKINE | THE BOOTS COMPANY PLC (GB) | 2023-03-09 | — | — | WO | claimed |
| WO-2023025416-A1 | COSMETIC COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 2023-03-02 | — | — | WO | claimed |
| EP-4140473-A1 | COSMETIC COMPOSITIONS | The Boots Company plc (GB) | 2023-03-01 | — | — | EP | claimed |
| EP-4141877-A1 | METHOD FOR IDENTIFYING A SOLVENT FOR A MATRIKINE | The Boots Company plc (GB) | 2023-03-01 | — | — | EP | claimed |
| WO-2022106057-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | claimed |
| EP-4000598-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | SRRM2, SGTA, QARS1 | DPP4 3448/4885DPP8 2364/4885DPP9 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.